John Rutkowski

Research activity per year

Fingerprint

Dive into the research topics where John Rutkowski is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

2 Active

ABLE 32: A Phase 3b, Randomized, Controlled Study of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)
Rutkowski, J. (PI)
Ferring Pharmaceuticals A/S
05/15/25 → 12/31/27
Project: Research
A phase 3, randomised, multi-center, open label Study to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in...
Rutkowski, J. (PI)
Ferring Pharmaceuticals A/S
05/15/25 → 12/31/28
Project: Research

6 Article
1 Comment/debate

Genital burn injuries: Insights from 10 years of consumer product-related incidents
Dovirak, I., Arbel, E. J., Reese, A. D., O'Shea, A. W., Evancho, P. C., Burke, M. S. & Rutkowski, J., Jun 2025, In: Burns. 51, 5, 107457.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Corrigendum to “Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report” [Urol Case Rep (March 2024) 102701] (Urology Case Reports (2024) 53, (S221444202400055X), (10.1016/j.eucr.2024.102701))
Arbel, E. J., Dinerman, B. F., Rutkowski, J., Acosta, A. M. & Spencer, J., Sep 2024, In: Urology Case Reports. 56, 102832.
Research output: Contribution to journal › Comment/debate

Open Access
Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report
Arbel, E. J., Dinerman, B. F., Rutkowski, J., Acosta, A. M. & Spencer, J., Mar 2024, In: Urology Case Reports. 53, 102701.
Research output: Contribution to journal › Article › peer-review

Open Access
Triple Primary Malignancy Detection in an Elderly Male: A Case Report on Concurrent Prostate Cancer, Clear Cell Renal Cell Carcinoma, and Metastatic Melanoma Identified by PSMA PET-CT
Arbel, E. J., Dinerman, B. F. & Rutkowski, J. M., Jul 2024, In: Urology Case Reports. 55, 102793.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations
Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
Dinerman, B. F., Skomra, A., Dovirak, I. & Rutkowski, J., Nov 2024, In: Urology Case Reports. 57, 102833.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Scopus citations

John Rutkowski

Personal profile

Fingerprint

Collaborations and top research areas from the last five years

Dive into details

ABLE 32: A Phase 3b, Randomized, Controlled Study of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)

A phase 3, randomised, multi-center, open label Study to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in...

Genital burn injuries: Insights from 10 years of consumer product-related incidents

Corrigendum to “Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report” [Urol Case Rep (March 2024) 102701] (Urology Case Reports (2024) 53, (S221444202400055X), (10.1016/j.eucr.2024.102701))

Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report

Triple Primary Malignancy Detection in an Elderly Male: A Case Report on Concurrent Prostate Cancer, Clear Cell Renal Cell Carcinoma, and Metastatic Melanoma Identified by PSMA PET-CT

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency

John Rutkowski

Personal profile

Fingerprint

Collaborations and top research areas from the last five years

Grants & Projects

ABLE 32: A Phase 3b, Randomized, Controlled Study of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC)

A phase 3, randomised, multi-center, open label Study to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in...

Research output

Genital burn injuries: Insights from 10 years of consumer product-related incidents

Corrigendum to “Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report” [Urol Case Rep (March 2024) 102701] (Urology Case Reports (2024) 53, (S221444202400055X), (10.1016/j.eucr.2024.102701))

Primary testicular teratoid Wilms tumor in a 40-year-old male with retroperitoneal lymph node involvement: A case report

Triple Primary Malignancy Detection in an Elderly Male: A Case Report on Concurrent Prostate Cancer, Clear Cell Renal Cell Carcinoma, and Metastatic Melanoma Identified by PSMA PET-CT

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency